Psoriatic Arthritis

Patients with both chronic inflammatory disease and inflammatory bowel disease demonstrated higher health use and costs, compared with those with just chronic inflammatory disease, according to data published in BMC Rheumatology.

Treatment with TNF inhibitors are associated with an increased — albeit still low — risk for neuroinflammatory disease in patients with ankylosing spondylitis and psoriatic arthritis, but not rheumatoid arthritis, according to data published in the Annals of the Rheumatic Diseases.

A review of 75 adalimumab clinical trials in adult and pediatric patients demonstrated low rates of inflammatory bowel disease adverse events, according to data published in Arthritis Care & Research.

Adults aged 18 to 50 years with various rheumatic conditions experience significant arthritis-related financial burdens, often leading to considerable distress and anxiety, according to findings published in Arthritis Care & Research.

Psoriatic arthritis has an estimated incidence of six per 100,000 and a prevalence of around one to two per 1,000 in the general population.

SCOTTSDALE, Ariz. —Rheumatologists, focused as they are on inflammatory symptoms, are often less familiar with cardiovascular management, according to M. Elaine Husni, MD, MPH, of the Cleveland Clinic.

Psoriatic arthritis is often a painful comorbidity for patients with psoriasis — and an expensive one at that. A 2016 study published in Actas Dermo-Sifiliográficas found the disease comes with a price tag to the tune of US$15,000 per patient in Europe. However, that price is also based on biologic drug use that can be as much as 80% cheaper than those in the United States or Canada.

Patients with psoriasis carry a slightly increased risk for cancer, particularly keratinocyte cancer and lymphomas, according to data published in JAMA Dermatology.

Immune-mediated inflammatory diseases (IMIDs) are a group of clinically heterogeneous disorders, including rheumatoid arthritis, psoriasis, psoriatic arthritis, giant cell arteritis, systemic lupus erythematosus, and axial spondyloarthritis, that share a similar immunopathology. Recognizing the underlying immunopathological mechanisms of these disorders is essential for understanding how current and emerging therapies exert their effects. In this CME activity, recorded during the Association of Women in Rheumatology National Conference, experts in the field examine common signaling pathways in IMIDs, evaluate recent clinical evidence for available and emerging immune-based therapies that target these pathways, assess the utilization of biomarkers for the identification of patients with early inflammatory disease, and evaluate the mechanisms of cancer immunotherapies as they relate to both an antitumor response and the potential for autoimmunity.

MAUI, Hawaii — The past year was marked by an increase in head-to-head drug trials in psoriatic arthritis, according to a presentation at the 2020 Rheumatology Winter Clinical Symposium.